Approved HBV Drugs
Approved HBV Drugs
DDW 2013: Does HBV Suppression Prevent Liver Disease Progression?
- Details
- Category: HBV Treatment
- Published on Wednesday, 19 June 2013 00:00
- Written by Liz Highleyman
Chronic hepatitis B patients with cirrhosis may still experience liver disease progression even if they undergo antiviral treatment and achieve good virological response, according to a poster presented at the Digestive Disease Week meeting (DDW 2013) last month in Orlando.
DDW 2013: Tenofovir and Entecavir Effectively Suppress Hepatitis B Virus
- Details
- Category: HBV Treatment
- Published on Thursday, 06 June 2013 00:00
- Written by Liz Highleyman
The newer antivirals tenofovir (Viread) and entecavir (Baraclude) inhibit hepatitis B virus (HBV) replication more effectively than older agents, but good adherence is needed to maintain long-term viral suppression, according to a set of studies presented at the Digestive Disease Week meeting (DDW 2013) last month in Orlando.
AASLD 2012: Entecavir Shows Good Efficacy for Black and Hispanic Hepatitis B Patients
- Details
- Category: HBV Treatment
- Published on Tuesday, 18 December 2012 00:00
- Written by Liz Highleyman
The nucleoside analog entecavir (Baraclude) worked as well for previously untreated African-American and Hispanic/Latino hepatitis B patients as it did for the majority white and Asian study populations in prior clinical trials, according to a poster presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston.
Most Hepatitis B Patients Who Respond to Tenofovir Show Improved Liver Health at 5 Years
- Details
- Category: HBV Treatment
- Published on Thursday, 27 December 2012 00:00
- Written by Liz Highleyman
Treatment with tenofovir (Viread) remains safe and effective over 5 years, and people who achieve sustained viral load suppression experience improvement in liver histology, including regression of fibrosis and cirrhosis, according to study findings described in the December 7, 2012, advance online edition of The Lancet.
Hepatitis B Patients with HBeAg Seroconversion on Treatment May Not Have Durable Response
- Details
- Category: HBV Treatment
- Published on Tuesday, 23 October 2012 00:00
- Written by Liz Highleyman
People with chronic hepatitis B virus (HBV) who achieve hepatitis B "e" antigen (HBeAg) seroconversion when treated with nucleoside/nucleotide analogs are more likely to experience HBeAg seroreversion and HBV reactivation than those with natural clearance, according to a study described in the November 15, 2012, Journal of Infectious Diseases.
More Articles...
- Entecavir (Baraclude) Label Adds Data on Black Patients and Liver Transplant Recipients with HBV
- Entecavir Alone Works as Well as Combo for First-time Hepatitis B Treatment
- Adefovir-resistant Hepatitis B Virus Can Remain Susceptible to Tenofovir
- Heavy Alcohol Use Impairs Biochemical Response to Entecavir for Chronic Hepatitis B
Web Design and Development by